US4686104A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of treating bone disorders
Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1986-04-22
•
Granted: 1987-08-11
•
Expires: 2006-04-22
Abstract
Abstract Metal-containing compounds have been found to decrease calcium resorption from bone. These compounds, when administered to patients who are suffering from diseases characterized by accelerated bone resorption, impede the flow of bone calcium into the blood and increase the calcium content of bone tissue.
Inventors
- 👤 Richard S. Bockman
- 👤 Raymond P. Warrell, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:17
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/24; A61K33/243
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
40 words
A method of decreasing bone resorption comprising administering to a subject with a bone resorptive disorder a pharmaceutically acceptable composition containing a germanium or platinum containing compound useful in decreasing bone resorption in an amount sufficient to cause bone resorption.
Claim 2
Independent Claim
40 words
A method of decreasing bone resorption comprising administering to a subject with a bone resorptive disorder a pharmaceutically acceptable composition containing a germanium or platinum containing compound useful in decreasing bone resorption in an amount sufficient to cause bone resorption.
Claim 3
Dependent Claim
12 words
A method as in claim 1, wherein said disease is periodontal disease.
Claim 4
Dependent Claim
12 words
A method as in claim 1, wherein said disease is cancer related.
Claim 5
Dependent Claim
11 words
A method as in claim 1, wherein said disease is hypercalcemia.
Claim 6
Dependent Claim
11 words
A method as in claim 1, wherein said disease is osteoporosis.
Claim 7
Dependent Claim
24 words
A method as in claim 1, wherein said disease is caused by a parathyroid hormone, a cytokine, or other bone-resorbing factor lymphokine related compound.
Claim 8
Dependent Claim
13 words
A method as in claim 1, wherein said disease is malignant bone metastases.
Claim 9
Dependent Claim
12 words
A method as in claim 1, wherein said disease is Paget's disease.
Claim 10
Dependent Claim
17 words
A method as in claim 1, wherein said disease is an inflammatory disorder of bones or joints.
Claim 11
Dependent Claim
12 words
A method as in claim 1, wherein said subject is a human.
Claim 12
Dependent Claim
13 words
A method as in claim 1, wherein said subject is a veterinary subject.
Claim 13
Dependent Claim
26 words
A method as in claim 1, wherein said compound is administered intra-orally in a topical formulation comprising a concentrated rinse, gel, or other pharmaceutically acceptable carrier.
Claim 14
Dependent Claim
15 words
A method as in claim 1, wherein said compound is administered intravenously, subcutaneously, or intramuscularly.
Claim 15
Dependent Claim
15 words
A method as in claim 1, wherein said compound is administered by continuous intravenous infusion.
Claim 16
Dependent Claim
22 words
A method of claim 1, wherein said compound is administered by intravenous injection comprising an amount ranging from about 1-450 mg/sq m/day.
Claim 17
Dependent Claim
18 words
A method as in claim 1, wherein said compound is administered orally, topically, sublingually, per rectum or transdermally.
Claim 18
Dependent Claim
26 words
A method as in claim 1, wherein said compound is administered orally, topically, sublingually, per rectum or transdermally in an amount ranging from about 0.5-20 grams/day.
Claim 19
Dependent Claim
14 words
A method as in claim 1, wherein said compound is a platinum containing compound.
Claim 20
Dependent Claim
14 words
A method as in claim 1, wherein said compound is a germanium containing compound.
Claim 21
Dependent Claim
13 words
A method as in claim 18, wherein said compound is cis-diammine dichloro-platinum II.
Claim 22
Dependent Claim
14 words
A method as in claim 18, wherein said compound cis-diammine 1,1-cyclobutane dicarboxylate platinum II.
Claim 23
Dependent Claim
11 words
A method as in claim 19, wherein said compound is spirogermanium.
Claim 24
Dependent Claim
17 words
A method as in claim 20, wherein said compound is administered by intravenous, intramuscular, or subcutaneous injection.
Claim 25
Dependent Claim
23 words
A method as in claim 20, wherein said compound is administered in an amount ranging from about 1 to about 120 mg/sq m/day.
Claim 26
Dependent Claim
17 words
A method as in claim 21, wherein said compound is administered by intravenous, intramuscular, or subcutaneous injection.
Claim 27
Dependent Claim
23 words
A method as in claim 21, wherein said compound is administered in an amount ranging from about 1 to about 450 mg/sq m/day.
Claim 28
Dependent Claim
23 words
A method as in claim 21, wherein said compound is administered in an amount ranging from about 3 to about 100 mg/sq m/day.
Claim 29
Dependent Claim
17 words
A method as in claim 22, wherein said compound is administered by intravenous, intramuscular, or subcutaneous injection.
Claim 30
Dependent Claim
23 words
A method as in claim 22, wherein said compound is administered in an amount ranging from about 0.5 to about 100 mg/sq m/day.
Claim 31
Independent Claim
18 words
A method as in claims 22 or 24, wherein said compound is administered orally, sublingually, rectally, or transdermally.
Claim 32
Dependent Claim
22 words
A method as in claim 22, wherein said compound is administered in an amount ranging from about 0.5 to about 20 grams/day.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-08-10 | 1991-02-09 | 1991-08-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-08-10 | 1995-02-09 | 1995-08-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-08-10 | 1999-02-09 | 1999-08-11 | $7700.00 | Window Closed / Lapsed |